WeVote
Log In

Bill

Bill

A 5317

Requires health insurance carriers to provide opportunity to clinical laboratory and laboratory services provider to participate as preferred or contracting provider in carriers' provider network.

2026-2027 Regular Session

Health insurers must invite and evaluate clinical labs to become in-network preferred providers, expanding lab network access and competition.

0
WeVote Research Nonpartisan
Bill Summary · A 5317

Summary of A-5317 (Session 222, New Jersey)

Purpose and intent

A-5317 requires health insurance carriers to provide clinical laboratories and laboratory services providers with the opportunity to participate as preferred or contracting providers in the carriers' networks. The bill aims to promote access to laboratory services, promote competition among laboratories, and ensure that laboratory providers have avenues to contract with carriers on terms similar to other in-network providers.

Key provisions

  • Provider participation opportunity: Health insurance carriers must offer clinical laboratories and laboratory services providers the chance to become preferred or contracting (in-network) providers under the carrier’s network arrangements.
  • Contracting engagement: Carriers must engage eligible laboratory providers in the contracting process, giving them the opportunity to negotiate terms for inclusion in the network.
  • Non-discrimination in process (conceptual): The bill implies a framework to ensure laboratory providers are not unfairly excluded from network contracting opportunities that are available to other types of providers.
  • Network adequacy and access considerations: By expanding the pool of contracting laboratories, the bill seeks to improve patient access to timely and appropriate laboratory testing through in-network providers.
  • Terms of participation: While the bill establishes the opportunity to participate, it may permit carriers to set standard contracting terms and credentialing requirements, subject to any additional regulatory constraints that apply to the contracting process (details would be specified in the implementing regulations or the bill’s text).

Who/what would be affected

  • Laboratory providers: Clinical laboratories and laboratory service providers would gain a defined pathway to become preferred or contracting providers within health insurance networks.
  • Health insurance carriers: Carriers would be required to create or maintain processes to invite and evaluate laboratory providers for network contracting. They may need to adjust contracting workflows, credentialing, and rate-setting practices.
  • Patients: Potential indirect benefits include broader access to in-network laboratory services, improved negotiation for lab rates, and possibly lower out-of-pocket costs for covered lab testing when using in-network labs.

Procedural and timeline aspects

  • The bill would become law after the standard legislative process in New Jersey concludes with passage by both legislative chambers and signing by the Governor (or effective upon enactment as provided in the bill). Specific effective dates, enrollment periods for providers, and any transitional provisions would be defined in the bill’s text.

Potential impact and considerations

  • Access and cost implications: Expanded laboratory network participation could enhance patient access to covered lab services and potentially influence lab pricing dynamics through increased contracting opportunities.
  • Market competition: Encourages broader competition among laboratories supplying in-network services, which could affect payer negotiations and laboratory service pricing.
  • Implementation considerations: Carriers may need to adjust provider enrollment systems, credentialing timelines, and dispute resolution processes to accommodate the expanded opportunity for laboratory participation.

Note: This summary reflects the bill’s general objectives and likely effects based on the title and summary provisions. For precise requirements, definitions, eligibility criteria, timelines, and any exemptions or regulatory details, please refer to the bill’s full text and any accompanying fiscal notes or regulatory impact statements.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.